Updates are available Correction dated 2025-07-03
Click to view Correction: https://doi.org/10.1007/s00429-025-02967-9
-
Authors
Omholt, Stig W.
Lejneva, Raissa
Donate, Maria Jose Lagartos
Caponio, Domenica
Fang, Evandro Fei
Kobro-Flatmoen, Asgeir
-
Funding
Funding for this research was provided by:
Olav Thon Stiftelsen
Norges Forskningsråd
Cure Alzheimer’s Fund (282952)
Cure Alzheimer’s Fund (282952)
Cure Alzheimer’s Fund (282952)
Helse Sør-Øst RHF
Molecule AG/VITADAO (282942)
Molecule AG/VITADAO (282942)
Molecule AG/VITADAO (282942)
NordForsk Foundation (119986)
NordForsk Foundation (119986)
NordForsk Foundation (119986)
National Natural Science Foundation of China (81971327)
National Natural Science Foundation of China (81971327)
National Natural Science Foundation of China (81971327)
Akershus University Hospital
Civitan Norges Forskningsfond (281931)
Civitan Norges Forskningsfond (281931)
Civitan Norges Forskningsfond (281931)
Czech Republic-Norway KAPPA programme (TO01000215)
Czech Republic-Norway KAPPA programme (TO01000215)
Czech Republic-Norway KAPPA programme (TO01000215)
NTNU Norwegian University of Science and Technology
- License Information
-
More Information
Article History
Received: 8 January 2024
Accepted: 3 June 2024
First Online: 25 June 2024
Change Date: 28 June 2025
Change Type: Update
Change Details: The original online version of this article was revised due to incorrect figure and text . Now, it has been Corrected.
Change Date: 3 July 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00429-025-02967-9
Declarations
:
: E.F.F. is the co-owner of Fang-S Consultation AS (Organization number 931 410 717); he has an MTA with LMITO Therapeutics Inc (South Korea), a CRADA arrangement with ChromaDex (USA), a commercialization agreement with Molecule AG/VITADAO; he is a consultant to Aladdin Healthcare Technologies (UK and Germany), the Vancouver Dementia Prevention Centre (Canada), Intellectual Labs (Norway), MindRank AI (China), and NYO3 (Norway and China).
: All procedures were approved by the Norwegian Animal Research Authority, and follow the European Convention for the Protection of Vertebrate Animals used for Experimental and Other Scientific Purposes. The Regional Committees for Medical and Health Research Ethics, Norway (permit 82685) approved the use of archival postmortem human brain sections.
: All authors consent to publication of this manuscript.
